| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Allarity Therapeutics (NASDAQ:ALLR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of...
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ: ALLR) with a Buy and raises the price target ...
-SEC Filing